Neuphoria Therapeutics Inc.: Form 20-F for the period ended Jun 30, 2022
Filed with the SEC on Oct 14, 2022 and accepted by EDGAR at Oct 14, 2022, 13:27 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 12 months2021-07-01 to 2022-06-30 | AUD 263.6k | ifrs-full:Revenue |
| Income tax | 12 months2021-07-01 to 2022-06-30 | −AUD 191.8k | ifrs-full:IncomeTaxExpenseContinuingOperations |
| Net income | 12 months2021-07-01 to 2022-06-30 | AUD 913.4k | ifrs-full:ProfitLossAttributableToOwnersOfParent |
| Diluted EPS | 12 months2021-07-01 to 2022-06-30 | −AUD 0.02 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months2021-07-01 to 2022-06-30 | −AUD 0.02 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months2021-07-01 to 2022-06-30 | −AUD 21.8m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months2021-07-01 to 2022-06-30 | AUD 1.5k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | At period end2022-06-30 | AUD 33.6m | ifrs-full:CashAndCashEquivalents |
| Current assets | At period end2022-06-30 | AUD 41.8m | ifrs-full:CurrentAssets |
| Total assets | At period end2022-06-30 | AUD 65.3m | ifrs-full:Assets |
| Current liabilities | At period end2022-06-30 | AUD 3.4m | ifrs-full:CurrentLiabilities |
| Total liabilities | At period end2022-06-30 | AUD 8.4m | ifrs-full:Liabilities |
| Shares outstanding | At period end2022-06-30 | 1,353,350,744 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000950170-22-019563. Last ingested by Listed: Oct 24, 2026, 15:10 ET. Listed shows no prices and gives no investment advice.